Abbott Laboratories (ABT) Q2 2026: EPS Beat and Raised Guidance Explained
As seen on the 24/7 Wall St. homepage on July 16, 2026.
Abbott beat on adjusted EPS and raised full-year guidance to $5.45 to $5.60 as the Exact Sciences acquisition fueled a 13% revenue surge, though continuous glucose monitor competition and a declining Nutrition business keep near-term headwinds in play.
Continue ReadingShow less
Abbott reported adjusted earnings per share of $1.31 for Q2 2026, topping the consensus estimate of $1.28 by about 2.6%. Revenue came in at $12.59 billion against expectations of roughly $12.52 billion, a beat of just over 0.6%. The Exact Sciences acquisition was the headline driver, fueling a 13% surge in revenue that gave the top line a meaningful lift. Full-year adjusted EPS guidance was raised to a range of $5.45 to $5.60.
The beat continues a streak of incremental outperformance that stretches back through recent quarters, though the margin of the wins has varied. Q4 2025 was the standout in recent history at $1.50 reported versus $1.49 estimated, while Q1 2026 came in exactly at the consensus of $1.15. The Q2 2026 result represents the largest percentage EPS beat in the past two quarters.
Sponsored
_________________________________
What's Your Number...?
Here's a question most people 5y from retirement can't answer: at your current savings rate, how much do you need, and how long will it actually last? A good advisor can put a date on that in a single meeting. SmartAsset's free quiz matches you with up to three fiduciary advisors serving your area, so you can get YOUR retirement number now (sponsor)
__________________________________________
Not everything in the print pointed upward. Growing competition in the continuous glucose monitor market and a declining Nutrition business remain active headwinds that investors will want to track as the year progresses. How Abbott manages those pressures while integrating Exact Sciences will be the key story to follow into the back half of 2026.
Mentioned: ABT